Jonathan Rubin, MD, MBA, has been the Chief Medical Officer and Senior Vice President of Research & Development at Supernus Pharmaceuticals, Inc. since January 1, 2021. Before joining the Company on February 10, 2020, as Senior Vice-President, Clinical Research and Medical Affairs, Dr. Rubin was Chief Medical Officer of Atentiv, Inc. from 2018 to 2020, where he was responsible for clinical strategy and the design of clinical trials. From 2017 to 2018, Dr. Rubin was a clinical consultant to Chondrial Therapeutics, Inc. responsible for developing clinical strategy and trials. From 2013 to 2017, Dr. Rubin was Chief Medical Officer of Alcobra, Inc., where he was responsible for oversight of the company’s clinical development, medical affairs, biometrics and pharmacovigilance departments, and he participated in the completion of two Phase III studies in ADHD and assisted with orphan drug and fast track designations for product candidates. From 2007 to 2013, Dr. Rubin was Medical Director of Clinical Development and Medical Affairs for Shire Pharmaceuticals, where he supported the company’s ADHD portfolio and assisted with the design, execution and interpretation of Phase II, Phase IIIB and Phase IV studies. Prior to entering the biopharmaceutical industry, Dr. Rubin was in private practice as a Developmental-Behavioral and General Pediatrician for 16 years. Dr. Rubin was a pediatric resident at Albert Einstein/Montefiore Hospital in the Bronx, New York and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Dr. Rubin received his M.D. from the University of Connecticut School of Medicine, his Master of Business Administration from the Columbia School of Business and his Bachelor of Science in molecular biophysics and biochemistry from Yale University.